Scalper1 News
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck reported the much-anticipated interim data from its C-Swift trial , which analysts thought could challenge market leader Gilead Sciences (GILD) if it could show high cure rates at four weeks to six weeks, Scalper1 News
Scalper1 News